Oscar Health, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated February 3, 2022, reports the closing of a material definitive agreement by Oscar Health, Inc. The transaction involves the issuance and sale of convertible senior notes to institutional investors.
Key Financial Metrics and Transaction Details
- Debt Issuance: $305,000,000 aggregate principal amount of 7.25% Convertible Senior Notes due 2031.
- Interest Rate: 7.25% per annum, payable in cash semi-annually (June 30 and December 31), commencing June 30, 2022.
- Conversion Price: Approximately $8.32 per share (reflecting a 38% premium to the Class A common stock price on January 26, 2022).
- Maximum Dilution: Up to 50,580,407 shares of Class A Common Stock may be issued upon conversion.
- Maturity Date: December 31, 2031.
- Settlement: At the Company's election, settlement may be in shares, cash, or a combination thereof.
Material Changes and Terms
The filing details the entry into an Indenture with U.S. Bank National Association as trustee. The Notes are senior, unsecured obligations. Key terms include:
- Conversion Rights: Holders may convert only upon certain events before August 31, 2031. After this date, conversion is at the holder's election until the second trading day before maturity.
- Repurchase Rights (Purchasers): Initial purchasers have the right to require the Company to repurchase notes on June 30 of 2027, 2028, 2029, and 2030.
- Redemption Rights (Company): The Company may not redeem the Notes prior to December 31, 2026. Redemption is permitted thereafter only if the stock price exceeds 200% of the conversion price for at least 20 trading days within a 30-day period.
- Fundamental Change: Holders may require repurchase for cash upon a fundamental change.
Guidance, Risks, and Contingencies
The filing outlines specific "Events of Default," including payment defaults, failure to comply with covenants, bankruptcy, and defaults on other indebtedness exceeding $25,000,000. In the event of a bankruptcy-related default, all principal and accrued interest become immediately due. The filing does not provide forward-looking financial guidance, revenue projections, or management commentary on operational performance.
Investor Verification Checklist
- Verify the impact of the 7.25% interest expense on future cash flow and net income.
- Assess the potential dilution of up to 50.6 million shares if conversion occurs.
- Review the specific covenants in the Indenture (Exhibit 4.1) regarding asset sales and mergers.
- Monitor the stock price relative to the $8.32 conversion price and the 200% redemption threshold.
- Confirm the use of proceeds from the $305 million issuance, which is not detailed in this specific 8-K text.